Synthetic peptide corresponding to the amino acids 2123 - 2132 (CTIDGKKYYFN) of the native molecule conjugated to Keyhole limpet Haemocyanin.
NB100-62473 is specific for Clostridium difficile Toxin A, a gram-positive motile bacterium which is the leading cause of diarrhoea in developed countries. The incidence of disease in humans varies greatly with age, spore density, and the administration of antibiotics. Toxin A (TcdA) is a large exotoxin which is an essential virulence factor for C. difficile infection. TcdA has a molecular weight of 308kD and is a glucosyltransferase, which irreversibly inactivates the Ras family of small GTPases to disrupt many important signalling pathways.
Protein G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Alternate Names for Clostridium Difficile Toxin A Antibody
Clostridia are toxin-producing anaerobic bacteria that cause a number of serious diseases, including tetanus, botulism, and tissue infections. Clostridia normally inhabit the human intestinal tract, soil, and decaying vegetation. All species of clostridia produce toxins. Some clostridial diseases, such as botulism and the various diarrheal illnesses, result solely from the toxin without any bacterial invasion of tissue. In other clostridial diseases, such as tetanus and clostridial wound infections, there is both tissue invasion and toxin production.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Publications for Clostridium Difficile Toxin A Antibody (NB100-62473)(1)
FAQs for Clostridium Difficile Toxin A Antibody (NB100-62473). (Showing 1 - 1 of 1 FAQ).
I am seeking monoclonal antibodies specific for the C Terminal binding regions of clostridum difficile toxins A and B (aa1852-2366)?
I would recommend catalog # NB100-62473. Although it is a polyclonal, it is the only one that we know binds to the C-Terminal portion of the protein. The other antibodies we have against both targets are synthesized from the full length sequence. We do not routinely epitope map our antibodies so we cannot be certain where they are binding. This polyclonal is synthesized against a small 10 amino acid region of the protein so it should be highly specific to that location.